Sphingolipid profiling as a biomarker of type 2 diabetes risk: evidence from the MIDUS and PREDIMED studies

Sphingolipid profiling as a biomarker of type 2 diabetes risk: evidence from the MIDUS and PREDIMED studies

Abstract Background Type 2 diabetes (T2D) has become a worldwide pandemic. While ceramides may serve as intermediary between obesity-related lipotoxicity and T2D, the relationship with simple glycosphingolipids remains uncertain. The aim of this study was to characterize the associations between blo...

Full description

Bibliographic Details
Main Authors: Loni Berkowitz, Cristina Razquin, Cristian Salazar, Fiorella Biancardi, Ramón Estruch, Emilio Ros, Montserrat Fitó, Dolores Corella, Christopher L. Coe, Carol D. Ryff, Miguel Ruiz-Canela, Jordi Salas-Salvado, Daniel Wang, Frank B. Hu, Amy Deik, Miguel A. Martínez-Gonzalez, Attilio Rigotti
Format: Article
Language:English
Published: BMC 2024-12-01
Series:Cardiovascular Diabetology
Subjects:
Type 2 diabetes
Sphingolipids
Ceramides
Lactosylceramides
Insulin resistance
Online Access:https://doi.org/10.1186/s12933-024-02505-7

Internet

https://doi.org/10.1186/s12933-024-02505-7

Similar Items